Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys PRAX Stock
Rep. Gilbert Ray Cisneros Jr. made a purchase of Praxis shares valued between $1,001 and $15,000 on September 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Praxis Precision Medicines, Inc. ($PRAX) stock on September 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $PRAX is down 0.3% after 1 week and down 14.0% to date (from the $281 close on Sep 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Praxis Precision Medicines, Inc. ($PRAX) | Buy | Sep 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
PRAX
Praxis Precision Medicines, Inc.
Key Points
- On September 29, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Praxis Precision Medicines, valued between $1,001 and $15,000, with the transaction disclosed on October 12.
- The stock of Praxis recently traded around $244.58 as of October 16, 2026, after the purchase was made, showing a potential interest in the biotechnology sector.
- Other institutional investors like Jupiter Topco LLC and FMR, LLC have significant stakes in Praxis, holding shares valued at approximately $827.2 million and $560.1 million, respectively.
Get $PRAX trade alerts by text
We text you when insiders, Congress or big funds trade $PRAX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Praxis Precision Medicines, Inc. alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr. bought shares of Praxis Precision Medicines, Inc. (NasdaqGS: PRAX) valued between $1,001 and $15,000 on September 29, 2026. This transaction was disclosed in a periodic transaction report filed under the STOCK Act on October 12, 2026. Cisneros is a Democrat representing California's 31st district in the House of Representatives.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
Inside Gilbert Ray Cisneros Jr.'s Trade
Cisneros's purchase of Praxis shares reflects a growing interest in the healthcare sector.
Other Institutional Activity in Praxis
Several other institutional investors have also been active in Praxis Precision Medicines. Jupiter Topco LLC increased its holdings by 1,710,687 shares, bringing its total to 3,421,374 shares worth about $827.2 million. FMR, LLC added 156,016 shares, resulting in a total of 2,316,907 shares valued at approximately $560.1 million. BlackRock Inc. trimmed its stake by 32,316 shares, ending up with 2,292,585 shares worth about $554.3 million. Perceptive Advisors LLC and Baker Bros. Advisors, LP held steady with 2,035,986 and 1,753,198 shares, respectively.
Praxis Precision Medicines, Inc. Stock Down 18.2%
As of October 16, 2026, Praxis shares traded recently around $244.58. The timing of Cisneros's purchase comes as the stock remains a notable player in the biotech sector, focusing on innovative treatments for central nervous system disorders. The company has a clinical-stage pipeline, which may attract further interest as it develops its therapies.
Recent Earnings
Praxis Precision Medicines reported a trailing twelve-month (TTM) earnings per share (EPS) of -$12.97, indicating it is currently not profitable. The next earnings report is scheduled for November 9, 2026, which may provide more insights into the company's financial health and future prospects.
Insider Buying and Selling at Praxis Precision Medicines, Inc.
On June 24, 2026, Jill Desimone, a director at Praxis, sold 11,600 shares valued at approximately $3.6 million. This transaction occurred before Cisneros's recent purchase, showcasing some insider activity at the company.
Analysts Set New Price Targets
On August 21, 2026, Goldman Sachs maintained a "Buy" rating on Praxis with a price target of $575, up from a previous target of $470. HC Wainwright & Co. and Needham also reiterated their "Buy" ratings with price targets of $1,201 and $582, respectively, on September 24, 2026. More recently, on October 6, HC Wainwright reiterated its target of $1,201, while BTIG raised its target from $810 to $826.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company based in Boston, MA. It focuses on developing therapies for central nervous system disorders characterized by an imbalance of neuronal excitation and inhibition. The company's innovative platforms aim to create precision therapies that could address significant unmet medical needs in this area.
Bottom Line
Gilbert Ray Cisneros Jr.'s recent purchase of Praxis shares highlights his interest in the biotechnology sector. With the next earnings report set for November 9, 2026, investors will be watching closely for updates on the company's progress and financial performance. This trade follows his previous activity, including a sale of shares in The Cooper Companies on June 5, 2026.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $PRAX (Sep 29, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts